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Background: Tumor cells benefit from their ability to avoid apoptosis and invade other tissues. The endoplasmic
reticulum (ER) membrane protein Sec62 is a key player in these processes. Sec62 is essential for cell migration and
protects tumor cells against thapsigargin-induced ER stress, which are both linked to cytosolic Ca2+. SEC62 silencing
leads to elevated cytosolic Ca2+ and increased ER Ca2+ leakage after thapsigargin treatment. Sec62 protein levels
are significantly increased in different tumors, including prostate, lung and thyroid cancer.
Methods: In lung cancer, the influence of Sec62 protein levels on patient survival was analyzed using the
Kaplan-Meier method and log-rank test. To elucidate the underlying pathophysiological functions of Sec62, Ca2+
imaging techniques, real-time cell analysis and cell migration assays were performed. The effects of treatment
with the calmodulin antagonists, trifluoperazine (TFP) and ophiobolin A, on cellular Ca2+ homeostasis, cell
growth and cell migration were compared with the effects of siRNA-mediated Sec62 depletion or the expression
of a mutated SEC62 variant in vitro. Using Biacore analysis we examined the Ca2+-sensitive interaction of Sec62
with the Sec61 complex.
Results: Sec62 overproduction significantly correlated with reduced patient survival. Therefore, Sec62 is not only
a predictive marker for this type of tumor, but also an interesting therapeutic target. The present study suggests
a regulatory function for Sec62 in the major Ca2+ leakage channel in the ER, Sec61, by a direct and Ca2+-sensitive
interaction. A Ca2+-binding motif in Sec62 is essential for its molecular function. Treatment of cells with calmodulin
antagonists mimicked Sec62 depletion by inhibiting cell migration and rendering the cells sensitive to thapsigargin
treatment.
Conclusions: Targeting tumors that overproduce Sec62 with calmodulin antagonists in combination with targeted
thapsigargin analogues may offer novel personalized therapeutic options.
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Cancer is one of the most common deadly diseases [1], and
the proportion of patients dying because of malignant
disease is increasing every year [2]. Lung cancer is of
particular concern with a five-year survival rate below
20% [3]. Therapeutic opportunities are scarce for patients
suffering from squamous cell carcinoma (SCC) of the lung
[4]. We have recently reported SEC62 as a new candidate
oncogene, as it is significantly overexpressed with elevated
protein levels in SCC [5].
Sec62 is an essential protein in yeast and part of the
Sec62/Sec63 sub-complex of the SEC complex, acting as
a docking site for posttranslational protein transport [6].
Studies in mammals have shown that Sec62 is associated
with the heterotrimeric Sec61 complex and Sec63 [7,8],
and that it participates in the targeting and translocation of
small pre-secretory proteins to the endoplasmic reticulum
(ER) [9,10]. Mammalian Sec62 can also interact with the
ribosome, thereby regulating translation [11]. Elevated
Sec62 protein levels are functionally linked to increased
cell migration capability [12] and reduced sensitivity to
thapsigargin-induced ER stress [13], both of which are
tightly regulated by the cytosolic Ca2+ concentration
[14-16]. Previously, we have shown that reduced Sec62
protein levels lead to an at least two-fold increase in
basal cytosolic Ca2+ and a much greater increase in cyto-
solic Ca2+ concentration in response to thapsigargin treat-
ment (i.e., increased ER Ca2+ leakage) [13]. These results
demonstrate a significant influence of Sec62 on ER Ca2+
homeostasis, making Sec62 a promising target for new
therapeutic approaches. Regulation of cytosolic Ca2+ levels
by targeting this protein may induce anti-metastatic and
anti-proliferative effects.
In the present study, we used small molecule inhibitors
of the Ca2+-binding protein, calmodulin, to mimic the
phenotypes previously observed after SEC62 silencing. This
approach provided new insight into the physiological func-
tion of Sec62 and may lead to a new therapeutic strategy
for personalized cancer therapy.
Methods
Cell culture and tissue samples
PC3 (DSMZ no. ACC 465), HeLa (DSMZ no. ACC 57),
A549 (DSMZ no. ACC 107), BC01 (kindly provided by G.
Unteregger, Saarland University Hospital, Department
of Urology and Pediactric Urology), BHT 101 (DSMZ
no. ACC 279), ML1 (DSMZ no. ACC 464) and HEK293
(DSMZ no. ACC 305) cells were cultured at 37°C in
DMEM medium (Gibco Invitrogen, Karlsruhe, Germany)
containing 10% fetal bovine serum (FBS; Biochrom, Berlin,
Germany) and 1% penicillin/streptomycin (PAA, Pasching,
Austria) in a humidified environment with 5% CO2. H1299
cells (ATCC no. CRL-5803D) were cultured in RPMI1640
medium (PAA) containing the same supplements. We usedstably transfected HEK293 cells expressing plasmid-encoded
wild-type SEC62 (pSEC62-IRES-GPF) or an empty control
plasmid (pIRES-GPF) [5]. A plasmid encoding SEC62 with
a D308A point mutation (pSEC62D308A-IRES-GPF) was
generated using the QuikChange Site-Directed Mutagenesis
Kit (Stratagene, La Jolla, CA, USA) according to the man-
ufacturer’s instructions. The plasmid was sequenced to
confirm the point mutation. A stably transfected cell line
expressing this mutant gene was generated by transfecting
2.4 × 105 HEK293 cells in a 6-well plate using FuGeneHD
Reagent (QIAGEN, Hilden, Germany) according to the
manufacturer’s instructions. After 72 h, the medium was re-
placed with normal culture medium containing 1% G418
and the cells were cultured until selection was achieved.
After harvesting, the cells were diluted to a density of 1 cell
per 100 μl, and 100 μl were seeded in each well of a 96-well
plate in medium containing 1% G418. Clones originating
from a single cell were selected and analyzed for Sec62 con-
tent. All experiments using stably transfected cell lines were
performed in normal growth medium containing 1% G418.
Stably transfected HEK293 cells were used for migration as-
says, as transient transfection or treatment with FuGeneHD
transfection reagent strongly inhibits cell migration.
We analyzed Sec62 levels in cancerous and tumor-free
lung tissue from 70 non-small cell lung cancer (NSCLC)
patients with pathologically confirmed adenocarcinoma
(AC) or squamous cell carcinoma (SCC) using western
blot with β-actin as a loading control. We calculated the
relative elevation in the Sec62 protein content (rSec62 =
[Sec62tumor/b-actintumor]/[Sec62tumor-free/b-actintumor-free])
in the tumor [5]. All patients (n = 70) and the subgroups
of AC (n = 35) and SCC (n = 35) patients were divided
into two groups based on the median rSec62 value, and
survival analyses were performed using the Kaplan-Meier
method and the log-rank test. Only samples from patients
who gave signed informed consent were used. All samples
were received for therapeutic or diagnostic purpose and
anonymized. Therefore, according to the guidelines of the
local ethics board (“Ethikkommision der Ärztekammer
des Saarlandes”) and the statement of the national ethics
committee (nationaler Ethikrat (Hrsg.): Biobanken für die
Forschung. Stellungnahme. Berlin 2004 [http://www.ethikrat.
org/dateien/pdf/NER_Stellungnahme_Biobanken.pdf]) they
can be used without specific approval by an ethics board.
Western blot
Protein in lysates from 2 × 105 cultured cells was quantified
by western blot analysis. We used an affinity-purified
polyclonal rabbit anti-peptide antibody directed against
the C-terminus of human Sec62, a polyclonal rabbit
anti-BiP antibody, a polyclonal rabbit anti-peptide anti-
body directed against the C-terminus of human Sec61α,
and a monoclonal murine anti-β-actin antibody (Sigma
Aldrich, Taufkirchen, Germany, A5441-.5ML). The primary
Linxweiler et al. BMC Cancer 2013, 13:574 Page 3 of 14
http://www.biomedcentral.com/1471-2407/13/574antibodies were visualized using an ECLTM Plex goat anti-
rabbit IgG-Cy5 or ECLTM Plex goat anti-mouse IgG-Cy3
conjugate (GE Healthcare, Munich, Germany), and the
Typhoon-Trio imaging system (GE Healthcare) in combin-
ation with Image Quant TL software 7.0 (GE Healthcare).
We determined the ratio of Sec62, Sec61α and BiP relative
to β-actin.
Silencing of gene expression by siRNA
For gene silencing, 5.4 × 105 cells were seeded in 6-cm
dishes containing normal culture medium. The cells
were transfected with SEC62-UTR siRNA (CGUAAA
GUGUAUUCUGUACtt; Ambion, Life Technologies,
Carlsbad, CA, USA), SEC62 siRNA (GGCUGUGGCCAAG
UAUCUUtt; Ambion), SEC61A1 siRNA (GGAAUUUGCC
UGCUAAUCAtt, QIAGEN, Hilden, Germany), or control
siRNA (AllStars Neg. Control siRNA; QIAGEN) using
HiPerFect Reagent (QIAGEN) according to the manufac-
turer’s instructions. After 24 h, the medium was changed
and the cells were transfected a second time. Silencing
efficiency was evaluated by western blot analysis. The
maximum silencing effect was seen 72 h (SEC62 siRNAs)
or 96 h (SEC61A1 siRNA) after the first transfection.
Real-time cell proliferation analysis
The xCELLigence SP system (Roche Diagnostics GmbH,
Mannheim, Germany) was used for real-time analysis of
cell proliferation. In this system, 1.0 × 104 or 2.0 × 104
stably transfected HEK293 cells, untreated HEK293, PC3
or HeLa cells, or PC3 cells pretreated with siRNA in 6-
cm dishes were seeded into a 96-well e-plate (Roche
Diagnostics GmbH) according to the manufacturer’s in-
structions. Cells pretreated with siRNA were seeded
24 h after the second transfection. When cells were
treated with thapsigargin, TFP or ophiobolin A, the
treatment was performed at least 4 h after seeding the
plates. Cell proliferation was monitored for 53–96 h and
the data was evaluated with RTCA 1.2 software (Roche
Diagnostics GmbH). Thapsigargin was used at concen-
trations of 6 or 10 nM, because these concentrations did
not affect cell growth. This is in contrast to the live-cell
calcium imaging experiments, where 1 μM thapsigargin
was used to visualize short-term calcium effects moni-
tored only over a time span of up to 1200 s.
Peptide spot binding assay
Thirteen peptides spanning the N-terminus of the human
Sec61α protein were synthesized on cellulose membranes
via a C-terminal attachment as described previously
[17,18]. The peptides consisted of 12 amino acid residues
with an overlap of 10 residues and were incubated in bind-
ing buffer (30 mM Tris–HCl, pH 7.4, 170 mM NaCl,
6.4 mM KCl, 5% sucrose, 0.05% Tween20) with Sec62-
C-6His (1 μM), which was purified from Escherichia colias described previously [11]. To detect bound protein,
the membranes were washed twice with binding buffer,
incubated with anti-His-POD-coupled antibody (1:1000,
QIAGEN), washed twice with binding buffer again, in-
cubated with ECL (GE Healthcare) and visualized using
a lumi-imaging system (Roche Diagnostics GmbH).
Surface plasmon resonance spectroscopy
Surface plasmon resonance (SPR) spectroscopy was per-
formed in a BIAlite upgrade system (Biacore, Freiburg,
Gerrmany). Peptides representing the N-terminus of
Sec61 (AIKFLEVIKPFC) or the N-terminus of TRAM
(VLSHEFELQNGADC) were immobilized in the meas-
uring cell or control cell, respectively, on a CM5 sensor
chip using ligand-thiol-coupling according to the man-
ufacturer’s protocol. Measurements were performed at
a flow rate of 10 μl/min in a Ca2+−free buffer containing
10 mM HEPES-KOH, pH 7.4, 150 mM NaCl, 2 mM
MgCl, 6.4 mM KCl and 0.005% surfactant. For interaction
analysis, E. coli-purified Sec62-C-6His (1 μM) [11] in buffer
minus Ca2+ or in the same buffer containing 2 mM Ca2+,
or the Ca2+-containing buffer alone was passed over the
chip. Response units are shown as the difference between
the measuring and control cells. The analysis was carried
out using BIA evaluation software version 3.1 (Biacore)
with 1:1 binding models and mass transfer.
Migration potential analysis
Migration was tested using the BD Falcon FluoroBlok
system (BD, Franklin Lakes, NJ, USA) in 24-well inserts.
A total of 2.5 × 104 stably transfected HEK293 cells, or un-
treated PC3 or HeLa cells were loaded in normal medium
containing 0.5% FBS. When DMSO, TFP or ophiobolin A
was used, the drugs were added to the top and bottom
chambers at various concentrations. The inserts were
placed in medium with 10% FBS as a chemoattractant.
After 72 h, the cells were fixed with methanol and stained
with DAPI, and migrating cells were analyzed on the back
of the membrane using fluorescence microscopy.
Live-cell calcium imaging
For live-cell Ca2+ imaging, HeLa cells were loaded with
4 μM FURA-2 AM (Molecular Probes, Eugene, OR, USA)
in DMEM for 45 min at room temperature as described
previously [19,20]. Two washes were performed with a
Ca2+-free buffer (140 mM NaCl, 5 mM KCl, 1 mM MgCl2,
0.5 mM EGTA and 10 mM glucose in 10 mM HEPES-
KOH, pH 7.35) and the experiments were carried out
in the same solution. A ratiometric measurement was
performed for 3 min to determine the initial cytosolic
[Ca2+]. The measurement was continued after the addition
of 1 μM thapsigargin or - to measure store operated
calcium entry (SOCE) - 2.5 mM Ca2+. Cells pretreated












































































Figure 1 Sec62 is a prognostic marker for NSCLC patients. A,
Patients with rSec62 < 2.1 exhibited significantly longer survival
compared with those with rSec62 ≥ 2.1 (P < 0.001). B, The survival
benefit of a low Sec62 protein level in the lung cancer tissue was
significant in patients with SCC (P < 0.001). C, The survival benefit
was not significant in patients with AC (P = 0.054).
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changes in cytosolic [Ca2+]. Data were collected by an
iMIC microscope and polychromator V (Till Photonics,
Graefelfing, Germany) by alternating excitation between
340 and 380 nm, and measuring the emitted fluorescence
at 510 nm (dichroic, DCLP410; emitter filter LP470;
Till Photonics). Images containing 50–60 cells/frame
were sampled every 3 sec. FURA-2 signals were recorded
as an F340/F380 ratio, where F340 and F380 correspond
to the background-subtracted fluorescence intensities at
340 and 380 nm, respectively. The cytosolic [Ca2+] was
estimated from the ratio measurements using an estab-
lished calibration method [21].
ER luminal Ca2+ was determined using HeLa-CES2 cells
that contain ER lumenal carboxylesterase and allow efficient
dye loading of the ER, as previously described [22]. Cells
were loaded with 4 μM Fluo5N AM (solubilized in Pluronic
F-127) in HBSS (Gibco) for 15 min at 37°C, washed with
HBSS and incubated for another 30 min at 25°C to re-
move remaining cytosolic dye. After 1 min incubation in
Ca2+-free buffer, buffer (0.1% DMSO, solvent control),
ophiobolin A (100 μM) or TFP (10 μM) were added, sam-
ples were measured for 2 min, and then 1 μM thapsigargin
was added to unmask the passive Ca2+ efflux from the
ER. After 8 min, 5 μM ionomycin was applied to release
the total ER Ca2+ of the cells. Data were collected by the
iMIC microscope with excitation at 490 nm and meas-
urement of the emitted fluorescence at 530 nm. Images
containing 10–25 cells/frame were sampled every 3 s.
A τ1/2-value was calculated for each curve as the time
point at which 50% reduction of fluorescence signal
was achieved after addition of thapsigargin.
Data were analyzed using Excel 2007 and Origin 6.1.
Results
Sec62 levels in cancer tissue predicts survival of
NSCLC patients
In our previous study, we detected SEC62 amplification
and overexpression in NSCLC that did not correlate with
patient age or sex but, at least for SCC, correlated with the
appearance of lymph node metastases (higher Sec62 levels
in N + tumors compared with N0 tumors) and the grade of
differentiation (higher Sec62 levels in poorly differentiated
G3 tumors compared with G2 tumors) [5]. Therefore,
in the present study, we tested whether lower Sec62
levels in cancer tissue are associated with longer patient
survival, which would indicate whether Sec62 can serve
as a prognostic marker. We investigated the association
between the rSec62 values of 70 NSCLC patients from
our previous study [5] and these patients’ survival starting
from the date of diagnosis. Patients were divided into two
groups based on their rSec62 value using a threshold of
2.1 (all patients, Figure 1A), 3 (SCC patients, Figure 1B)
and 1.85 (AC patients, Figure 1C), representing the medianrSec62 value of the respective group. Survival analysis was
visualized using Kaplan-Meier diagrams. Using the log-rank
test, we observed a highly significant survival rate in the low
rSec62 group compared with the high rSec62 group among
all lung cancer patients, and SCC patients (P= 0.001 for all
NSCLC patients, P= 0.001 for SCC patients, P = 0.054 for
AC patients). The clinical relevance of the Sec62 protein
level for SCC of the lung is even more important given that
the increased Sec62 protein level also protects tumor cells
from thapsigargin therapy [13].
Treatment with calmodulin antagonists mimics changes
in the cytosolic calcium concentration induced by
SEC62 silencing
Previously, we have suggested SEC62 silencing as a pos-
sibility for overcoming the protective effect of SEC62
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led to an increase in cytosolic Ca2+ and enhanced Ca2+
leakage from the ER in response to thapsigargin [13].
We also discovered a crucial influence of calmodulin
on ER Ca2+ homeostasis; ER Ca2+ leakage is limited by
Ca2+-dependent binding of calmodulin to the Sec61 com-
plex [17,23]. The delivery of siRNAs for therapeutic ap-
plications is still problematic. Therefore, to determine
whether Sec62 regulates calmodulin binding to the Sec61
complex or modulates the Sec61 complex, we examined
the effects of the calmodulin antagonists, trifluoperazine
(TFP) and ophiobolin A, on Ca2+ homeostasis compared
with the effects of siRNA-mediated Sec62 depletion.
Interestingly, all three approaches resulted in a comparable
increase in cytosolic Ca2+ with or without thapsigargin
treatment (Figure 2A). The results strongly suggest that
a similar molecular mechanism leads to dysregulation of
cellular Ca2+ homeostasis after SEC62 silencing and after
treatment with calmodulin antagonists.
To verify that indeed Ca2+ leakage from the ER is re-
sponsible for the increase in cytosolic Ca2+ concentration
after treatment with ophiobolin A or TFP, we first used
HeLa-CES2 cells in combination with Fluo5N to directly
measure changes in ER luminal Ca2+. We observed an ini-
tial Ca2+-release from the ER after addition of calmodulin
antagonists and a significantly higher efflux in the ophio-
bolin A or TFP pretreated cells in response to thapsigargin
(Figure 2B), with τ1/2-values of 163 s for the buffer control,
87 s after pretreatment with ophiobolin A and 65 s after
pretreatment with TFP. Next, we asked if the calmodulin
antagonists influence the store operated calcium entry
(SOCE). To this end, we measured the cytosolic Ca2+
concentration after treating the cells externally with a
Ca2+-containing buffer instead of thapsigargin and EGTA.
These experiments disclosed that SOCE was also signifi-
cantly stimulated by pretreatment with calmodulin antag-
onists. Moreover, a comparison between cells treated with
control siRNA and cells treated with two different siRNAs
directed against SEC61A1 indicated a crucial function
of the Sec61 channel in SOCE under these conditions
(Figure 2C). We note that we used a HeLa cell-based
model system rather than lung cancer cells for two main
reasons. First, the HeLa cells provide a well-established
model system for SEC61A1 or SEC62 gene silencing, and
live-cell Ca2+ imaging. Second, we were able to compare
the results of live-cell Ca2+ imaging experiments on cells
treated with SEC61A1 or SEC62 siRNA with our previous
observations (Figure 2A–D) [13,24].
Furthermore, we examined whether the effect of Sec62
on ER Ca2+ leakage can be linked to the Ca2+-permeable
Sec61 complex as has been previously shown for the
effects of TFP and ophiobolin A [17,24]. To address
this question, we treated HeLa cells for 96 h with SEC62
siRNA, SEC61A1 siRNA, SEC62 plus SEC61A1 siRNA,or a negative control siRNA. Simultaneous silencing of
SEC61A1 and SEC62 by siRNA had an inhibitory effect
on SEC62 silencing-induced Ca2+ efflux (Figure 2D).
Western blot analysis indicated that the silencing efficiency
of both siRNAs was > 80% (Figure 2D, insert). Thus, cal-
modulin antagonists and Sec62 contribute to reducing
Ca2+ leakage from the ER at the Sec61 complex level.
As has already been shown for calmodulin [17], Sec62
presumably acts by direct interaction with Sec61α.
Peptide binding experiments were carried out to directly
demonstrate the putative interaction of Sec62 with Sec61α
and identify the Sec62 binding site. Peptide spots that
correspond to the human Sec61α were synthesized on
cellulose membranes. The peptides consisted of 12 amino
acid residues and overlapped adjacent peptides by 10
residues. The peptides were incubated with the C-terminal
cytosolic domain of the double-spanning membrane
protein, Sec62. The C-terminal domain of Sec62 (Sec62C)
preferentially bound to the N-terminal peptide of Sec61α
(amino acid residues 1–16; Figure 2E, insert). In subsequent
SPR spectroscopy analysis (Figure 2E), the interaction
of Sec62C with the N-terminal peptide of Sec61α was
confirmed. Sec62C showed more pronounced binding to
Sec61α in the absence of Ca2+ than in its presence. In
silico analysis of the Sec62 sequence (www.bioinformatics.
org/calpred/ index.html) identified a potential EF hand in
the C-terminal domain of vertebrate Sec62 (Figure 3A),
which may explain this Ca2+ effect (amino acid residues
308–319, see below).
Mutation in a predicted calcium-binding motif in the
C-terminal domain of Sec62 leads to a dominant-negative
effect on cell migration and ER calcium leakage
Previously, we showed that Sec62 depletion inhibits the
spread of metastatic tumor cells and increases cell sen-
sitivity to Ca2+-driven ER stress [12,13]. By introducing
the D308A mutation into the predicted Ca2+-binding
motif within the C-terminal domain of Sec62, we confirmed
the function of Sec62 in regulating ER Ca2+ homeostasis
(Figure 3A). In this experiment, the expression of plasmid-
encoded SEC62-WT or SEC62D308A was evaluated by
quantitative western blot analysis of the stably transfected
HEK293 cell lines. We observed a nine-fold increase in
Sec62 in the presence of pSEC62-WT and an almost
five-fold increase in Sec62 in the presence of pSEC62D308A
in comparison with the control plasmid (Figure 3B).
We then compared stably transfected HEK293 cells
overexpressing the plasmid-encoded mutant SEC62
(pSEC62D308A-IRES-GFP) with cells overexpressing SEC62-
WT (pSEC62-IRES-GFP). Overproduction of Sec62-WT
led to increased migration, which is in agreement with
our previous observations [5]. In contrast, overproduction
of the mutant Sec62 protein, even in the presence of the
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Figure 2 SEC62 silencing and calmodulin antagonists affect cellular calcium homeostasis similarly. A, HeLa cells were transfected with
SEC62- or control siRNA, after 96 h loaded with FURA2-AM, and subjected to Ca2+ imaging. After 60 s in Ca2+-free buffer, cells were treated with
ophiobolin A (100 μM), TFP (10 μM), or buffer for 10 min, and then thapsigargin was added. The graphs represent the mean cytosolic Ca2+
concentration of 182 (control siRNA), 325 (control siRNA + ophiobolin A), 198 (control siRNA + TFP) or 82 cells (SEC62 siRNA). B, HeLa-CES2 cells
were loaded with Fluo5N-AM. After 60 s in Ca2+-free buffer, ophiobolin A, TFP, or buffer was added, samples were measured for 2 min, then
thapsigargin and after 5 min ionomycin was added. C, HeLa cells were transfected with SEC61A1- or control siRNA, after 96h loaded with
FURA2-AM, and after 60 s in Ca2+-free buffer treated with ophiobolin A, TFP or buffer. After 10 min Ca2+-solution was added (2.5 mM free Ca2+).
D, HeLa cells were transfected with SEC62- , SEC61A1-, a combination of both siRNAs, or control siRNA, loaded with FURA2-AM, incubated in
Ca2+-free buffer and subsequently treated with thapsigargin. The graphs represent the mean cytosolic Ca2+ concentration of 547 (control siRNA), 353
(SEC62 siRNA), 495 (SEC61A1 siRNA), or 395 cells (SEC62 + SEC61A1 siRNA). The insert shows the silencing efficiency determined by western blot (n=3).
E, SPR spectroscopy was performed with Sec61α N-terminal peptide (measuring-cell) and TRAM N-terminal peptide (control-cell). Ca2+-containing buffer
(control) or purified Sec62-C-His in buffer with or without Ca2+was passed over both cells. The insert shows a peptide spot binding assay. Peptides
spanning the N-terminus of Sec61α were synthesized on a cellulose membrane and incubated with Sec62-C-His (1 μM) in binding buffer. Bound protein
was detected using anti-His-POD coupled antibody and visualized with a luminescence-imaging system.
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Also, the sensitivity to thapsigargin (Figure 3D) and
thapsigargin-induced Ca2+ leakage from the ER increased
after SEC62D308A expression (Figure 3E). Overall, SEC62-
WT overexpression did not affect cell growth or ER Ca2+
leakage, whereas SEC62D308A overexpression led to a
phenotype comparable to that of SEC62 silencing.
These experiments clearly indicate a direct influence of the
predicted EF hand motif in Sec62 on ER Ca2+ homeostasis
and its direct connection to the observed phenotypes.HeLa and HEK293 cells are more sensitive to TFP
treatment than PC3 cells
To study the influence of TFP and ophiobolin A on cellu-
lar processes other than Ca2+ homeostasis, we analyzed
the proliferation of PC3 and HeLa cells in the presence of
these two calmodulin antagonists. We also analyzed
HEK293 cells with respect to their TFP sensitivity. The
main aim of this set of experiments was to determine the
TFP and ophiobolin A concentrations that do not inhibit
cell growth in subsequent cell migration or thapsigargin
Control plasmid
pSEC62WT
1   MAERRRHKKRIQEVGEPSKEEKAVAKYLRFNCPTKSTNMMGHRVDYFIAS  50
51  KAVDCLLDSKWAKAKKGEEALFTTRESVVDYCNRLLKKQFFHRALKVMKM  100
101 KYDKDIKKEKDKGKAESGKEEDKKSKKENIKDEKTKKEKEKKKDGEKEES  150
151 KKEETPGTPKKKETKKKFKLEPHDDQVFLDGNEVYVWIYDPVHFKTFVMG 200
201 LILVIAVIAATLFPLWPAEMRVGVYYLSVGAGCFVASILLLAVARCILFL 250
251 IIWLITGGRHHFWFLPNLTADVGFIDSFRPLYTHEYKGPKADLKKDEKSE  300
301 TKKQQKSDSEEKSDSEKKEDEEGKVGPGNHGTEGSGGERHSDTDSDRRED  350
































































































Figure 3 A mutation in the putative EF hand motif of Sec62 affects cell migration, growth and ER calcium efflux in a dominant-negative
manner. A, Sequence of the human Sec62 protein. Transmembrane domains 1 and 2 are indicated with a solid underline. The predicted EF hand
motif is indicated with a dotted underline. In the plasmid-encoded SEC62D308A, amino acid D308 (red) was replaced with an alanine. B, Sec62 protein
levels in stably transfected HEK293 cells were analyzed by western blot analysis. C, HEK293 cells stably transfected with pIRES-GFP-SEC62-WT,
pIRES-GFP-SEC62D308A or pIRES-GFP (control plasmid) were seeded in normal growth medium without FBS in the top chamber of a BD-Falcon
Fluoroblok migration system (24-well format). The lower chamber contained the same medium with 10% FBS as an attractant. After 72 h migrated cells
were fixed with methanol and DAPI stained. Migration was analyzed by fluorescence microscopy using a 10-fold objective magnification. Migrated cells
in at least five individual images were automatically counted using NIS-Elements AR Software (Nikon, Düsseldorf, Germany). The mean values and
standard deviation are shown in the diagram. D, Stably transfected HEK293 cells (5 × 103) were seeded in a 96-well ePlate and growth was examined
in the xCELLigence RTCA system. After 300 min, 6 nM thapsigargin (left panel) or 0.1% DMSO (solvent control, right panel) was added to each well. All
samples were measured in triplicate. E, Stably transfected HEK293 cells were seeded on glass slides in 6-cm dishes and loaded with FURA2-AM.
Forty-five minutes later the cells were used for Ca2+ imaging as described in the legend for Figure 2. After 60 s incubation with EGTA buffer, the cells
were treated with 1 μM thapsigargin. The curves shown in the diagram represent the mean cytosolic Ca2+ concentration of 158 cells (pSEC62-WT),
159 cells (pSEC62D308A) and 160 cells (control plasmid).
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sensitivity to ophiobolin A; both cell lines exhibited normal
growth behavior up to a concentration of 500 nM, whereas
higher concentrations significantly inhibited cell growth
(Figure 4A). In contrast, PC3 cells tolerated TFP up to
24 μM, while HeLa cells exhibited a time-limited growth
inhibition between 24 and 60 h after adding the com-
pound, indicating that HeLa cells were more sensitive to
TFP treatment than PC3 cells (Figure 4B). HEK293 cells
exhibited normal proliferation with up to 8 μM of TFP in
the medium, whereas cell growth was almost completely
inhibited with higher concentrations. Based on thesefindings, we used concentrations of up to 250 nM of
ophiobolin A and up to 8 μM of TFP as non-growth-
inhibiting conditions for all cell lines in the subsequent
experiments. Interestingly, the HeLa and HEK293 cells,
which were more sensitive to TFP treatment, also expressed
lower levels of Sec62 protein compared with PC3 cells.
This difference was not because of a lower ER content, as
the analyzed cell lines expressed similar levels of the ER
chaperone, BiP (Figure 4C). The sensitivity of different cell
lines to calmodulin antagonists may correlate with their
specific Sec62 protein content, as indicated by our previ-
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Figure 4 Reduced SEC62 expression correlates with slightly increased sensitivity to TFP in PC3 cells. A, Effect of ophiobolin A treatment
on the growth of PC3 and HeLa cells. PC3 or HeLa cells (1 × 104) were seeded in a 96-well ePlate and growth was examined by the xCELLigence
RTCA system. After 330 min, cells were treated with buffer alone or buffer + ophiobolin A at the indicated concentrations. All samples were
measured in triplicate. The cell index was normalized to the time point of cell treatment (330 min). B, The same analysis as described in A was
performed on PC3, HeLa and HEK293 cells after treatment with TFP at the indicated concentrations. C, Quantification of the ER proteins, Sec62
and BiP, by western blot analysis. D, PC3 or HeLa cells were seeded in normal growth medium without FBS and supplemented with ophiobolin
A, TFP or DMSO (control) at the indicated concentrations in the top chambers of a BD-Falcon Fluoroblok migration system (24-well format). The
upper chambers were set in the lower chambers, which contained the same medium with 10% FBS as an attractant. After 72 h (PC3) or 24 h
(HeLa), migrated cells were fixed with methanol and DAPI stained. Migration was analyzed by fluorescence microscopy. The quantitative data
from this experiment are shown in the diagram.
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http://www.biomedcentral.com/1471-2407/13/574against thapsigargin-induced ER stress [13]. The present
findings affirmed the direct role of Sec62 in the cellular
response to Ca2+-driven ER stress.
Treatment with calmodulin antagonists and SEC62
silencing result in comparable cellular phenotypes
Next, we investigated whether a strongly reduced migration
potential and increased sensitivity to thapsigargin-induced
ER stress can also be caused by TFP or ophiobolin A
treatment. First, the cell migration of PC3 and HeLa cells
was examined in the presence of increasing amounts of
ophiobolin A or TFP. We found a dose-dependent reduc-
tion in cell migration with both cell lines with both treat-
ments (Figure 4D). Again, HeLa cells were more sensitiveto the treatments than PC3 cells. To confirm the results,
we tested different human lung (H1299, A549 and BC01)
and thyroid cancer cell lines (BHT101 and ML1). We have
previously reported reduced migration of these cell lines
after transfection with SEC62 siRNA [5]. Here, we found
that 4 μM TFP and 100 nM ophiobolin A had the same
effect on each cell line, strongly inhibiting cell migration
without affecting cell proliferation (Figure 5A).
Because Sec62 depletion by siRNA transfection alone
was sufficient to block cell migration in previous experi-
ments [12], we tested whether SEC62 overexpression
can rescue ophiobolin A- or TFP-treated cells. We used
HEK293 cells, which only poorly migrate without treat-
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Figure 5 Calmodulin antagonist treatment affects cell migration, which can be overcome by SEC62 overexpression. A, Human lung
(BC01, H1299 and A549) and thyroid cancer cells (BHT101 and ML1) were seeded in normal growth medium without FBS and treated with either
ophiobolin A or TFP, and seeded in the top chamber of a BD-Falcon Fluoroblock migration system (24-well format). The upper chambers were
set in the lower chambers, which contained the same medium with 10% FBS as an attractant. After 72 h, migrated cells were fixed with methanol
and DAPI stained. Migration was analyzed by fluorescence microscopy. To exclude the possibility that the effects seen in the migration assay were
caused by effects on cell proliferation, the cells were also analyzed in the xCELLigence system. To this end, 1 × 104 cells were seeded in a 96-well
ePlate and growth was examined using the RTCA software. Three hundred minutes after seeding, the cells were treated with either ophiobolin A
(100 nM), TFP (4 μM) or DMSO (0.1%, solvent control). All samples were measured in triplicate. B, HEK293 cells stably transfected with a plasmid
encoding wild-type SEC62 (pSEC62-WT) or the respective control plasmid were seeded in normal growth medium without FBS and supplemented
with TPA (10 nM) and ophiobolin A at the indicated concentrations in the top chamber. Migration was analyzed as described in A. C, The
experiments described in B were performed in the presence of TFP instead of ophiobolin A at the indicated concentrations. D, Sec62 protein
content was analyzed in stably transfected HEK293 cells by western blot analysis.
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http://www.biomedcentral.com/1471-2407/13/57412-O-tetradecanoylphorbol 13-acetate (TPA), a drug that
down-regulates agonist-driven Ca2+ release from the ER
[25] and stimulates cell migration [26,27]. We compared
HEK293 cells stably transfected with a pIRES-GFP vector
(control plasmid) and HEK293 cells stably overexpressing
plasmid-encoded SEC62 (pSEC62-IRES-GPF). The migra-
tion of the control plasmid-transfected HEK293 cells was
completely inhibited by 100 nM ophiobolin A or 8 μM TFP
(Figure 5B and C). However, cells overexpressing SEC62
still migrated under these conditions (Figure 5B and C),
indicating that the Sec62 protein content resulted in highercell resistance to treatment with calmodulin antagonists.
Quantitative western blot analysis confirmed a four-fold
increase in Sec62 in the pSEC62-WT-carrying HEK293 cells
(Figure 5D). These observations support a Ca2+-dependent
influence of Sec62 on cell migration.
Growth inhibition induced by calmodulin antagonists is
enhanced by Sec62 depletion
Because treatment with calmodulin antagonists led to the
same phenotype as Sec62 depletion with respect to cell
migration, we next investigated whether this was also true
Linxweiler et al. BMC Cancer 2013, 13:574 Page 10 of 14
http://www.biomedcentral.com/1471-2407/13/574for the increased thapsigargin sensitivity of the cells.
PC3 cells were transfected with control siRNA or siRNA
specifically directed against the SEC62 mRNA, followed by
treatment with 10 nM thapsigargin in the presence of 8 μM
TFP or 0.1% DMSO (solvent control). Sec62-depleted
cells exhibited greater sensitivity to thapsigargin and
similar behavior to control siRNA-transfected cells after
TFP treatment, indicating a slightly weaker decline in the
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http://www.biomedcentral.com/1471-2407/13/574regarding the function of Sec62 under cellular stress
conditions.
Discussion
Sec62 as a new prognostic marker for NSCLC patients
Because SEC62 silencing inhibits cancer cell migration
and increases sensitivity to Ca2+-driven cellular stress,
we investigated whether Sec62 represents not only a
possible new target for anti-cancer therapies, but also a
prognostic marker for lung cancer patients. A low
rSec62 value predicts increased survival of NSCLC pa-
tients, with an even stronger predictive potential for
SCC patients. Together with our previous findings that
SEC62 is overexpressed and correlates with lymph
node metastasis (N + vs. N0) and cancer progression
(G3 vs. G2) in SCC of the lung [5], the results indicate
that Sec62 plays a crucial role in lung cancer biology
and is both a promising new target for cancer therapy
and a reliable marker of clinical outcomes. Additional
studies are needed to determine whether the role of
Sec62 as a prognostic marker is solely because of the
tumor cells’ dependency on a sufficient Sec62 level to
enable metastasis and resistance to Ca2+-driven cellu-
lar stress, or whether Sec62 has additional contributing
functions.
Phenotypic analogy of cellular calcium changes following
treatment with calmodulin antagonists provides new
insight into molecular events in Sec62-depleted cells
We have previously reported strong inhibition of cell
migration in different human cancer cells after Sec62
depletion by transfection with SEC62 siRNA [5,12].
SEC62 silencing markedly increased cell sensitivity to ER
stress induced by dysregulation of cellular Ca2+ homeosta-
sis, as shown by the more pronounced growth inhibition
of Sec62-depleted cells after treatment with the SERCA
inhibitor, thapsigargin, compared with control cells [5,13].
These results indicate that Sec62 plays a crucial role in
cell migration and the ER stress response, particularly
in cancer cells. However, we could not determine the
molecular mechanisms responsible for these phenomena,
as the function of Sec62 is only partially understood,
even under physiological conditions, with some evidence
for a role in protein transport at the ER of mammalian
cells [9,10]. Sec62 could be involved in the transport of
a particular subset of precursor proteins, including proteins
that play crucial roles in cell migration and the ER stress
response. However, we propose a model in which Sec62
influences these processes by regulating cellular Ca2+
homeostasis (Figure 7). This possibility is supported by
the key role of Ca2+ in cell migration and ER stress
[14,28-30], the potential EF hand motif in the cytosolic
C-terminus of Sec62, the increase in basal cellular Ca2+ in
response to SEC62 silencing, and the markedly elevatedcytosolic Ca2+ in response to thapsigargin treatment after
SEC62 silencing [13]. Though sparse evidence supports
the first theory, Sec62’s influence on Ca2+ homeostasis
is strongly supported by the present findings. Here, we
showed that Sec62 depletion by siRNA transfection
and treatment with calmodulin antagonists resulted in
very similar changes in basal cellular Ca2+ levels and
increased cytosolic Ca2+ concentrations after thapsi-
gargin treatment. We also found that the treatment of
different human cancer cells with calmodulin antago-
nists led to the same cellular phenotypes as observed
after SEC62 silencing, namely cell migration inhibition
and markedly higher cell sensitivity to thapsigargin-
induced ER stress. The crucial role of Sec62 in cellular
Ca2+ homeostasis was further supported by the synergistic
action of treatment with SEC62 siRNA and calmodulin
antagonists in regard to the sensitivity to thapsigargin-
induced ER stress and by the rescue of cell migration
by SEC62 overexpression in cells pretreated with cal-
modulin antagonists.
Furthermore, the dominant-negative phenotype induced
by mutation of the predicted EF hand motif in the Sec62
protein, which was completely congruent with the effects
of Sec62 depletion or treatment with calmodulin antago-
nists, strongly points to a direct regulation of Sec62 func-
tion by Ca2+ binding to the motif. The Sec61 complex has
recently been shown to form an important Ca2+ leakage
channel in the ER, the major cellular Ca2+ reservoir, and
that Ca2+ efflux via this polypeptide pore is regulated by
calmodulin [23] and the ER luminal Hsp70 chaperone,
BiP [31]. Taken together with our new findings that Ca2+
efflux from the ER after Sec62 depletion occurs through
the Sec61 complex, we propose a model in which Sec62 is
an additional regulator of the Sec61 Ca2+ leakage channel.
Sec62 regulates Ca2+ leakage via a direct interaction with
Sec61. The association of these two proteins has already
been demonstrated [7,8] and has been found to be Ca2+
sensitive (Figure 2D). Following our model, Sec62 senses
emanating Ca2+ via a microdomain in close proximity to
the Sec61 channel. After Ca2+ binding, Sec62 binding to
Sec61 is relieved, thereby uncovering the binding site
and facilitating the binding of Ca2+-calmodulin to Sec61
on the cytosolic surface of the ER, leading to closure of
the channel (Figure 7A and E). In this model, the Sec62
variant with the mutated EF hand (Sec62D308A) is no
longer able to sense the emanating Ca2+, and thus
closure of the Sec61 channel by Ca2+-calmodulin
binding would not occur, which explains the increased
Ca2+ response observed in our live-cell Ca2+ imaging
experiments. An additional mode of action of Sec62
on the luminal side is possible via a role in the recruit-
ment of BiP as a Ca2+ efflux-limiting factor via its inter-







































































































































































Figure 7 Model for Sec62’s influence on ER Ca2+ efflux via the Sec61 complex under various conditions. A, Physiological situation: most
Sec61 complexes are associated with Sec62/Sec63-complexes. Calcium ions (Ca2+) leaking through the channel to the cytosol are detected by
Sec62‘s EF hand, thus facilitating an interaction between Ca2+-CaM and the Sec61 complex and subsequent sealing of the channel. Sec62/Sec63-
free Sec61 complexes allow a basal leakage of Ca2+, which is counteracted by SERCA activity. B, SEC62 knockdown conditions: depletion of Sec62
leads to a lack of calcium detection by Sec62 on the cytosolic surface of the ER. Ca2+-CaM is no longer recruited to the Sec61 complex and Ca2+
leakage persists, resulting in a slightly increased cytosolic Ca2+ concentration and a predisposition of the cells to apoptosis. Hence, Ca2+-dependent
cell migration is inhibited. C, Compared with the situation described in B, the SERCA pump is inhibited by thapsigargin. The increased leakage
combined with the inactivated back-pumping leads to a dramatic elevation in the cytosolic Ca2+ concentration and the cells undergo apoptosis.
D, Trifluoperazine conditions: the situation described in B and C is mimicked by TFP treatment. Here, Sec62 still detects the leaking Ca2+, but the
Ca2+-CaM-Sec61 complex interaction is blocked by TFP. In the absence of thapsigargin, the lack of interaction leads to the situation described in B;
in the presence of thapsigargin, it leads to the situation described in C. E, Pathophysiological situation: an increased level of Sec62 protein probably
leads to sealing of more Sec61 complexes, which may reduce the cytosolic Ca2+ level and/or increase the ER Ca2+ concentration, thereby protecting
the cells against thapsigargin-induced ER stress.
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molecule treatment as a possible new therapeutic option
for cancer patients
Previous studies have shown that Sec62 depletion by
transfection with SEC62 siRNA leads to cell migration
inhibition and higher sensitivity to ER stress induced by
Ca2+ dysregulation [5,12,13]. Therefore, SEC62 silencing
seems to provide a potential approach for cancer treatment,
especially lung and thyroid cancer, as such treatment could
lead to reduced metastatic spread of tumor cells and higher
sensitivity to chemotherapies working via the induction of
ER stress. However, despite intensive studies over the pastfew decades [33-36], RNA interference remains unfeasible
for clinical treatment of human diseases, mainly because
of toxic side effects and problems in achieving adequate
concentrations in the target tissues [37]. Our present results
provide a potential strategy for overcoming these problems
with tumors that overproduce Sec62.
In the current study, we showed that treatment of
different human cancer cells with calmodulin antagonists
induced a Sec62-depletion phenotype, including cell mi-
gration inhibition and higher sensitivity to Ca2+-driven ER
stress. The same effects on tumor cell biology can be
expected by treating patients with these substances,
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anti-metastatic and anti-proliferative drugs [38-43]. In par-
ticular, TFP appears to be a promising candidate for trials
in animal models, and in human patients, because it has
previously been used as an antipsychotic and antiemetic
drug [44,45]. Treatment with calmodulin antagonists could
also provide the means for overcoming problems with
treating patients with high levels of Sec62 protein in tumor
cells [13]; here, a personalized therapeutic approach
that also targets the SERCA pump using thapsigargin
or tissue-specific peptide conjugates of thapsigargin
appears to be promising [46-50]. Based on the present
results, we propose combined treatment with TFP and
targeted thapsigargin as a powerful new strategy for treat-
ing patients with SCC of the lung (Figure 7D), which is es-
pecially important because the therapeutic options for this
malignancy are very limited and increased levels of Sec62
are a significant disadvantage in regard to survival.
Conclusions
The present study describes a new function of Sec62 in
regulating the calmodulin-mediated sealing of the Sec61
Ca2+ leakage channel in the ER, which may explain how
the up-regulation of SEC62 expression results in reduced
survival among lung cancer patients. Furthermore, it pro-
vides the first molecular insight into the mechanism of re-
sistance of Sec62-overproducing tumor cells to treatment
with thapsigargin. Using calmodulin antagonists, including
TFP, we can inhibit cancer cell migration and overcome the
problem of Sec62 overproduction in response to thapsigar-
gin, which may also improve the treatment of these cancer
entities in future combinatorial therapeutic strategies.
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